Biological variation of prostate specific antigen levels in serum: An evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients

Journal of Urology

Volumn 157, Issue 6, 1997, Pages 2183-2190

  Nixon, Randy G ^b   Wener, Mark H ^b   Smith, Katie M ^b   Parson, Robert E ^b   Strobel, Susan A ^b   Brawer, Michael K ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

prostate specific antigen; prostatic hypertrophy; prostatic neoplasms; time factors

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COHORT ANALYSIS; HUMAN; MALE; MEASUREMENT; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; SERUM;

EID: 0030985128     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64711-6     Document Type: Article

References (33)

1. Carter, H. B., Morrell, C. H., Pearson, J. D., Brant, L. J., Plato, C. C., Metter, E. J., Chan, D. W., Fozard, J. L. and Walsh, P. C.: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res., 52: 3323, 1992.
2. Smith, D. S. and Catalona, W. J.: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J. Urol., 152: 1163, 1994.
3. Porter, J. R., Hayward, R. and Brawer, M. K.: The significance of short-term PSA change in men undergoing ultrasound-guided prostate biopsy. J. Urol., part 2, 151:293A, abstract 264, 1994.
4. Catalona, W. J., Smith, D. S. and Ratliff, T. L.: Value of measurements of the rate of change of serum PSA levels in prostate cancer screening. J. Urol., part 2, 149: 300A, abstract 348, 1993.
5. Fraser, C. G. and Harris, E. K.: Generation and application of data on biological variation in clinical chemistry. Crit. Rev. Clin. Lab. Sci., 27: 409, 1989.
6. Fraser, C. G.: Biological variation in clinical chemistry. An update: collected data, 1988-1991. Arch. Path. Lab. Med., 116: 916, 1992.
7. Fritsche, H. A. and Babaian, R. J.: Analytical performance goals for measuring prostate-specific antigen. Clin. Chem., 39:1525, 1993.
8. Harris, E. K.: Statistical principles underlying analytic goal-setting in clinical chemistry. Amer. J. Clin. Path., 72: 374, 1979.
9. Vessella, R. L., Noteboom, J. and Lange, P. H.: Evaluation of the Abbott IMx automated immunoassay of prostate-specific anti-gen. Clin. Chem., 38: 2044, 1992.
10. Dnistrian, A. M., Schwartz, M. K., Smith, C. A., Nisselbaum, J. S. and Fair, W. R.: Abbott IMx evaluated for assay of prostate-specific antigen in serum. Clin. Chem., 38: 2140, 1992.
11. Schifman, R. B., Ahmann, F. R., Elvick, A., Ahmann, M., Coulis, K. and Brawer, M. K.: Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared. Clin. Chem., 33: 2086, 1987.
12. Glenski, W. J., Klee, G. G., Bergstralh, E. J. and Oesterling, J. E.: Prostate-specific antigen: establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations. Prostate, 21: 99, 1992.
13. Sokal, R. R. and Rohlf, F. J.: Biometry, 2nd ed. New York: Freeman, 1981.
14. Mettlin, C., Jones, G., Averette, H., Gusberg, S. B. and Murphy, G. P.: Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. Cancer, 43: 42, 1993.
15. Policy statements of the American Urological Association, Inc.: Early Detection of Prostate Cancer and Use of Transrectal Ultrasound. Baltimore: American Urological Association, p. 65, 1995.
16. Dejter, S. W., Jr., Martin, J. S., McPherson, R. A. and Lynch, J. H.: Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: a comparative evaluation. Urology, 32: 288, 1988.
17. Mannini, D., Maver, P., Aiello, E., Corrado, G., Vecchi, F., Bellanova, B. and Marengo, M.: Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer. Urol. Res., 16: 9, 1988.
18. Browning, M. C. K. and McFarlane, N. P.: Objective interpretation of results for tumour markers. J. Nucl. Med. Allied Sci., 34: 89, 1990.
19. El-Shirbiny, A. M., Nilson, T. and Pawar, H. N.: Serum prostate-specific antigen: hourly change/24 hours compared with prostatic acid phosphatase. Urology, 35: 88, 1990.
20. Panteghini, M., Pagani, F. and Bonora, R.: Pre-analytical and biological variability of prostatic acid phosphatase and prostate-specific antigen in serum from patients with prostatic pathology. Eur. J. Clin. Chem. Clin. Biochem., 30: 135, 1992.
21. Maatman, T. J.: Comparative analysis of fluctuation of serum tumor markers in advanced cancer of prostate. Urology, 42: 672, 1993.
22. Riehmann, M., Rhodes, P. R., Cook, T. D., Grose, G. S. and Bruskewitz, R. C.: Analysis of variation in prostate-specific antigen values. Urology, 42: 390, 1993.
23. Akimoto, S., Masai, M. and Shimazaki, J.: Relationship between diurnal rhythm of serum testosterone and two prostatic markers (PSA and PAP) in untreated prostate cancer. Urology, 43: 337, 1994.
24. Prestigiacomo, A. F. and Stamey, T. A.: Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J. Urol., 155: 1977, 1996.
25. Bunting, P. S.: A guide to the interpretation of serum prostate specific antigen levels. Clin. Biochem., 28: 221, 1995.
26. Wener, M. H., Daum, P. R. and Brawer, M. K.: Variation in measurement of prostate-specific antigen: importance of method and lot variability. Clin. Chem., 41: 1730, 1995.
27. Brawer, M. K., Daum, P., Petteway, J. C. and Wener, M. H.: Assay variability in serum prostate-specific antigen determination. Prostate, 27: 1, 1995.
28. Brawer, M. K., Bankson, D. D., Haver, V. M. and Petteway, J. C.: Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method. Prostate, in press.
29. Harris, E. K., Kanofsky, P., Shakarji, G. and Cotlove, E.: Biological and analytical components of variation in long-term studies of serum constituents in normal subjects. II. Estimating biological components of variation. Clin. Chem., 16: 1022, 1970.
30. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K. and Alfthan, O.: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222, 1991.
31. Christensson, A., Bjork, T., Nilsson, O., Dahlén, U., Matikainen, M. T., Cockett, A. T. K., Abrahamsson, P. A. and Lilja, H.: Serum prostate specific antigen complexed to α-1-antichymotrypsin as an indicator of prostate cancer. J. Urol., 150: 100, 1993.
32. Luderer, A. A., Chen, Y. T., Soriano, T. F., Kramp, W. J., Carlson, G., Cuny, C., Sharp, T., Smith, W., Petteway, J. and Brawer, M. K.: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology, 46: 187, 1995.
33. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L. and Nadler, R. B.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J.A.M.A., 274: 1214, 1995.